These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 32851128)

  • 1. Largest Experience of Safety and Efficacy of Patiromer in Solid Organ Transplant.
    Schnelle K; Winters H; Pesavento T; Singh P
    Transplant Direct; 2020 Sep; 6(9):e595. PubMed ID: 32851128
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Patiromer: a clinical review.
    Montaperto AG; Gandhi MA; Gashlin LZ; Symoniak MR
    Curr Med Res Opin; 2016; 32(1):155-64. PubMed ID: 26456884
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and Safety of Patiromer in Hyperkalemia: A Systematic Review and Meta-Analysis.
    Das S; Dey JK; Sen S; Mukherjee R
    J Pharm Pract; 2018 Feb; 31(1):6-17. PubMed ID: 28402156
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Patiromer in patients with kidney disease and hyperkalemia receiving RAAS inhibitors.
    Weir MR; Bakris GL; Bushinsky DA; Mayo MR; Garza D; Stasiv Y; Wittes J; Christ-Schmidt H; Berman L; Pitt B;
    N Engl J Med; 2015 Jan; 372(3):211-21. PubMed ID: 25415805
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of Patiromer on Hyperkalemia Recurrence in Older Chronic Kidney Disease Patients Taking RAAS Inhibitors.
    Weir MR; Bushinsky DA; Benton WW; Woods SD; Mayo MR; Arthur SP; Pitt B; Bakris GL
    Am J Med; 2018 May; 131(5):555-564.e3. PubMed ID: 29180023
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The tolerability and safety profile of patiromer: a novel polymer-based potassium binder for the treatment of hyperkalemia.
    Pitt B; Garza D
    Expert Opin Drug Saf; 2018 May; 17(5):525-535. PubMed ID: 29667438
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of Patiromer on Serum Potassium Level in Patients With Hyperkalemia and Diabetic Kidney Disease: The AMETHYST-DN Randomized Clinical Trial.
    Bakris GL; Pitt B; Weir MR; Freeman MW; Mayo MR; Garza D; Stasiv Y; Zawadzki R; Berman L; Bushinsky DA;
    JAMA; 2015 Jul; 314(2):151-61. PubMed ID: 26172895
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recent advances in pharmacological treatments of hyperkalemia: focus on patiromer.
    Epstein M; Pitt B
    Expert Opin Pharmacother; 2016 Jul; 17(10):1435-48. PubMed ID: 27180623
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of infant formula with patiromer dose dependently decreases potassium concentration.
    Paloian NJ; Bowman B; Bartosh SM
    Pediatr Nephrol; 2019 Aug; 34(8):1395-1401. PubMed ID: 30963285
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hepatitis C virus infection in nonliver solid organ transplant candidates and recipients.
    Aqel BA; Vargas HE
    Curr Opin Organ Transplant; 2015 Jun; 20(3):259-66. PubMed ID: 25944237
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and efficacy of patiromer use with tacrolimus in kidney transplant recipients.
    Rattanavich R; Malone AF; Alhamad T
    Transpl Int; 2019 Jan; 32(1):110-111. PubMed ID: 30444015
    [No Abstract]   [Full Text] [Related]  

  • 12. Patiromer: a significant advance in the management of hyperkalemia.
    Paton DM
    Drugs Today (Barc); 2015 Dec; 51(12):695-703. PubMed ID: 26798850
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Patiromer for Treatment of Hyperkalemia in the Emergency Department: A Pilot Study.
    Rafique Z; Liu M; Staggers KA; Minard CG; Peacock WF
    Acad Emerg Med; 2020 Jan; 27(1):54-60. PubMed ID: 31599043
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Food safety for the solid organ transplant patient: preventing foodborne illness while on chronic immunosuppressive drugs.
    Obayashi PA
    Nutr Clin Pract; 2012 Dec; 27(6):758-66. PubMed ID: 23100530
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Patiromer: A Review in Hyperkalaemia.
    Kim ES; Deeks ED
    Clin Drug Investig; 2016 Aug; 36(8):687-94. PubMed ID: 27380495
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Patiromer Decreases Serum Potassium and Phosphate Levels in Patients on Hemodialysis.
    Bushinsky DA; Rossignol P; Spiegel DM; Benton WW; Yuan J; Block GA; Wilcox CS; Agarwal R
    Am J Nephrol; 2016; 44(5):404-410. PubMed ID: 27784004
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-Effectiveness Analysis of Patiromer and Spironolactone Therapy in Heart Failure Patients with Hyperkalemia.
    Bounthavong M; Butler J; Dolan CM; Dunn JD; Fisher KA; Oestreicher N; Pitt B; Hauptman PJ; Veenstra DL
    Pharmacoeconomics; 2018 Dec; 36(12):1463-1473. PubMed ID: 30194623
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hyperkalemia treatment modalities: A descriptive observational study focused on medication and healthcare resource utilization.
    Desai NR; Rowan CG; Alvarez PJ; Fogli J; Toto RD
    PLoS One; 2020; 15(1):e0226844. PubMed ID: 31910208
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of Patiromer in Hyperkalemic Patients Taking and Not Taking RAAS Inhibitors.
    Kloner RA; Gross C; Yuan J; Conrad A; Pergola PE
    J Cardiovasc Pharmacol Ther; 2018 Nov; 23(6):524-531. PubMed ID: 30103622
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Real-world management of hyperkalemia with patiromer among United States Veterans.
    Kovesdy CP; Gosmanova EO; Woods SD; Fogli JJ; Rowan CG; Hansen JL; Sauer BC
    Postgrad Med; 2020 Mar; 132(2):176-183. PubMed ID: 31971043
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.